On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacﾒs COVID-19 vaccine candidate., Novartis planned to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. Delivery from the manufacturing site in Kundl, Austria, was expected to start in summer 2021.